Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Häufige urologisch-sexualmedizinische Themen in der Praxis sind das Thema des MMW-Webinars am 5. Juni von 17.30 bis 19 Uhr. Konkret geht es um die Frage, wann bei Harnwegsinfektionen auf Antibiotika verzichtet werden kann, und um ein Update zur Therapie von Libido- und Potenzstörungen des Mannes. Der dritte Vortrag behandelt sexuell übertragbare Krankheiten. Stellen Sie Ihre Fragen an die Experten und sammeln Sie 2 CME-Punkte. Jetzt gleich anmelden!
Erweiterte Suche
Anmelden
nach oben
Current Infectious Disease Reports
Erschienen in: Current Infectious Disease Reports 12/2016

01.12.2016 | Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE)

verfasst von: Dana R. Bowers, Vanthida Huang

Erschienen in: Current Infectious Disease Reports | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Carbapenems are the broadest spectrum antimicrobials utilized in the treatment of serious infections since the 1980s. Soon after their introduction, the discovery of carbapenem-resistant Enterobacteriaceae (CRE) was reported in the 1990s. Invasive CRE infections are associated with high mortality and limited treatment options making care for patients with these infections challenging for clinicians. Current practice has reverted back to the use of “older” antimicrobials, such as the polymyxins, tigecycline, and fosfomycin, to combat invasive CRE infections. However, recent approval of ceftazidime-avibactam has added another treatment option to the current antimicrobial armamentarium. Resistance among the “older” agents is still rare but has been reported. Currently, there are numerous agents that are under investigation as well as combination therapy that looks promising in the treatment of CRE infections.
Literatur
1.
Miyadera T, Sugimura Y, Hashimoto T, Tanaka T, Iino K, Shibata T, et al. Synthesis and in vitro activity of a new carbapenem, RS-533. J Antibiot (Tokyo). 1983;36:1034–9.CrossRef
2.
3.
Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45:1151–61.CrossRefPubMedPubMedCentral
4.
••Centers for Disease Control and Prevention. 2013, posting date. Threat Report 2013. [Online.] This report gives a list of priorities from the CDC about emerging resistant bacteria.
5.
Mathers AJ, Cox HL, Kitchel B, Bonatti H, Brassinga AK, Carroll J, et al. Molecular dissection of an outbreak of carbapenem-resistant enterobacteriaceae reveals Intergenus KPC carbapenemase transmission through a promiscuous plasmid. MBio. 2011;2:e00204–11.CrossRefPubMedPubMedCentral
6.
Endimiani A, Carias LL, Hujer AM, Bethel CR, Hujer KM, Perez F, et al. Presence of plasmid-mediated quinolone resistance in Klebsiella pneumoniae isolates possessing blaKPC in the United States. Antimicrob Agents Chemother. 2008;52:2680–2.CrossRefPubMedPubMedCentral
7.
Endimiani A, Hujer AM, Perez F, Bethel CR, Hujer KM, Kroeger J, et al. Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USA. J Antimicrob Chemother. 2009;63:427–37.CrossRefPubMedPubMedCentral
8.
Hsieh WS, Wang NY, Feng JA, Weng LC, Wu HH. Molecular surveillance and prevalence of carbapenem-resistant Enterobacteriaceae in Northern Taiwan. J Antimicrob Chemother. 2014;69:2871–3.CrossRefPubMed
9.
Hsieh WS, Wang NY, Feng JA, Weng LC, Wu HH. Types and prevalence of carbapenem-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex in Northern Taiwan. Antimicrob Agents Chemother. 2014;58:201–4.CrossRefPubMedPubMedCentral
10.
Bratu S, Landman D, Alam M, Tolentino E, Quale J. Detection of KPC carbapenem-hydrolyzing enzymes in Enterobacter spp. from Brooklyn, New York. Antimicrob Agents Chemother. 2005;49:776–8.CrossRefPubMedPubMedCentral
11.
Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother. 2005;49:3018–20.CrossRefPubMedPubMedCentral
12.
••O’Horo JC, Farrell A, Sohail MR, Safdar N. Carbapenem-resistant Enterobacteriaceae and endoscopy: An evolving threat. Am J Infect Control. 2016. This study reports on the increasing number of CRE infections from endoscopy and the changes that have been made by the FDA since.
13.
Neuner EA, Yeh JY, Hall GS, Sekeres J, Endimiani A, Bonomo RA, et al. Treatment and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Diagn Microbiol Infect Dis. 2011;69:357–62.CrossRefPubMedPubMedCentral
14.
van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75:115–20.CrossRefPubMedPubMedCentral
15.
••Dickstein Y, Edelman R, Dror T, Hussein K, Bar-Lavie Y, Paul M. Carbapenem-resistant Enterobacteriaceae colonization and infection in critically ill patients: a retrospective matched cohort comparison with non-carriers. J Hosp Infect. 2016. This study examined the colonization rate of CRE in the ICU and subsequent infections from the colonizing organism.
16.
Wang L, Lansing B, Symons K, Flannery EL, Fisch J, Cherian K, et al. Infection rate and colonization with antibiotic-resistant organisms in skilled nursing facility residents with indwelling devices. Eur J Clin Microbiol Infect Dis. 2012;31:1797–804.CrossRefPubMedPubMedCentral
17.
18.
••Wang Q, Zhang Y, Yao X, Xian H, Liu Y, Li H, Chen H, Wang X, Wang R, Zhao C, Cao B, Wang H. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis. 2016. Clinical risk factors and outcomes for CRE are presented in this article.
19.
•Bogan C, Kaye KS, Chopra T, Hayakawa K, Pogue JM, Lephart PR, et al. Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis. Am J Infect Control. 2014;42:612–20. An infection control article that stresses the impact of CRE isolation. CrossRefPubMed
20.
Teo J, Cai Y, Tang S, Lee W, Tan TY, Tan TT, et al. Risk factors, molecular epidemiology and outcomes of ertapenem-resistant, carbapenem-susceptible Enterobacteriaceae: a case-case–control study. PLoS One. 2012;7:e34254.CrossRefPubMedPubMedCentral
21.
Ahn JY, Song JE, Kim MH, Choi H, Kim JK, Ann HW, et al. Risk factors for the acquisition of carbapenem-resistant Escherichia coli at a tertiary care center in South Korea: a matched case–control study. Am J Infect Control. 2014;42:621–5.CrossRefPubMed
22.
••Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother. 2014;58:654–63. Excellent review on current treatment options in CRE.CrossRefPubMedPubMedCentral
23.
••Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL. Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect. 2014;20:862–72. Excellent review on current treatment options in CRE.CrossRefPubMed
24.
••Bogan C, Kaye KS, Chopra T, Hayakawa K, Pogue JM, Lephart PR, et al. Outcomes of carbapenem-resistant Enterobacteriaceae isolation: matched analysis. Am J Infect Control. 2014;42:612–20. A detailed review of polymyxins in CRE infections.CrossRefPubMed
25.
Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob. 2012;11:32.CrossRefPubMedPubMedCentral
26.
Sader HS, Castanheira M, Farrell DJ, Flamm RK, Mendes RE, Jones RN. Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY Antimicrobial Surveillance Program (2011–2014). Int J Antimicrob Agents. 2016;48:144–50.CrossRefPubMed
27.
••Mediavilla JR, Patrawalla A, Chen L, Chavda KD, Mathema B, Vinnard C, Dever LL, Kreiswirth BN. Colistin- and Carbapenem-Resistant Escherichia coli Harboring mcr-1 and blaNDM-5, Causing a Complicated Urinary Tract Infection in a Patient from the United States. MBio. 2016; 7. First case of colistin resistant CRE.
28.
Satlin MJ, Kubin CJ, Blumenthal JS, Cohen AB, Furuya EY, Wilson SJ, et al. Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine. Antimicrob Agents Chemother. 2011;55:5893–9.CrossRefPubMedPubMedCentral
29.
Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014;43:52–9.CrossRefPubMed
30.
Endimiani A, Patel G, Hujer KM, Swaminathan M, Perez F, Rice LB, et al. In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin. Antimicrob Agents Chemother. 2010;54:526–9.CrossRefPubMed
31.
Falagas ME, Maraki S, Karageorgopoulos DE, Kastoris AC, Mavromanolakis E, Samonis G. Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin. Int J Antimicrob Agents. 2010;35:240–3.CrossRefPubMed
32.
Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16:184–6.CrossRefPubMed
33.
Lahiri SD, Johnstone MR, Ross PL, McLaughlin RE, Olivier NB, Alm RA. Avibactam and class C beta-lactamases: mechanism of inhibition, conservation of the binding pocket, and implications for resistance. Antimicrob Agents Chemother. 2014;58:5704–13.CrossRefPubMedPubMedCentral
34.
••Lahiri SD, Mangani S, Jahic H, Benvenuti M, Durand-Reville TF, De Luca F, et al. Molecular basis of selective inhibition and slow reversibility of avibactam against class D carbapenemases: a structure-guided study of OXA-24 and OXA-48. ACS Chem Biol. 2015;10:591–600. This is a review article on avibactam, how it works and against what types of resistance mechanisms. CrossRefPubMed
35.
Vazquez JA, Gonzalez Patzan LD, Stricklin D, Duttaroy DD, Kreidly Z, Lipka J, et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin. 2012;28:1921–31.CrossRefPubMed
36.
Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, Phase II trial. J Antimicrob Chemother. 2013;68:1183–92.CrossRefPubMed
37.
Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, et al. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis. 2016;62:1380–9.CrossRefPubMedPubMedCentral
38.
Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, et al. Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis. 2016;16:661–73.CrossRefPubMed
39.
•Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother. 2014;69:2305–9. Meta-analysis of combination therapy for CRE.CrossRefPubMed
40.
Bulik CC, Nicolau DP. Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2011;55:3002–4.CrossRefPubMedPubMedCentral
41.
Hagihara M, Crandon JL, Urban C, Nicolau DP. Efficacy of doripenem and ertapenem against KPC-2-producing and non-KPC-producing Klebsiella pneumoniae with similar MICs. J Antimicrob Chemother. 2013;68:1616–8.CrossRefPubMed
42.
Wiskirchen DE, Crandon JL, Nicolau DP. Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae. Int J Antimicrob Agents. 2013;41:582–5.CrossRefPubMed
43.
Endimiani A, Hujer KM, Hujer AM, Armstrong ES, Choudhary Y, Aggen JB, et al. ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates. Antimicrob Agents Chemother. 2009;53:4504–7.CrossRefPubMedPubMedCentral
44.
Zhanel GG, Lawson CD, Zelenitsky S, Findlay B, Schweizer F, Adam H, et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev Anti-Infect Ther. 2012;10:459–73.CrossRefPubMed
45.
Incoroporated A. A study of plazomicin compared with colistin in patients with infection due to carbapenem-resistant enterobacteriacea (CRE) (CARE). National Library of Medicine, ClinicalTrials.gov. 2013.
46.
••Livermore DM, Mushtaq S, Warner M, Woodford N. In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60:3840–4. In vitro study for eravacyclin in CRE and Acinetobacter baumannii.CrossRefPubMedPubMedCentral
47.
Bassetti M, Righi E. Eravacycline for the treatment of intra-abdominal infections. Expert Opin Investig Drugs. 2014;23:1575–84.CrossRefPubMed
48.
Sutcliffe JA, O’Brien W, Fyfe C, Grossman TH. Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens. Antimicrob Agents Chemother. 2013;57:5548–58.CrossRefPubMedPubMedCentral
49.
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother. 2014;58:1847–54.CrossRefPubMedPubMedCentral
50.
Tetraphase Pharmaceuticals. Efficacy and safety of eravacycline compared with ertapenem in complicated intra-abdominal infections (IGNITE-1). National Library of Medicine, ClinicalTrials.gov. 2013.
51.
Tetraphase Pharmaceuticals. 2015 posting date. Tetraphase announce top-line results from IGNITE2 phase 3 clinical trial of eravacycline in CUTI. [Online.]
52.
Hecker SJ, Reddy KR, Totrov M, Hirst GC, Lomovskaya O, Griffith DC, et al. Discovery of a Cyclic Boronic Acid beta-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases. J Med Chem. 2015;58:3682–92.CrossRefPubMed
53.
Castanheira M, Mendes RE, Jones RN, Sader HS. Changes in the Frequencies of beta-Lactamase Genes among Enterobacteriaceae Isolates in U.S. Hospitals, 2012 to 2014: Activity of Ceftazidime-Avibactam Tested against beta-Lactamase-Producing Isolates. Antimicrob Agents Chemother. 2016;60:4770–7.CrossRefPubMed
54.
Wenzler E, Gotfried MH, Loutit JS, Durso S, Griffith DC, Dudley MN, et al. Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects. Antimicrob Agents Chemother. 2015;59:7232–9.CrossRefPubMedPubMedCentral
55.
Rempex Pharmaceuticals. A phase 3, multi-center, randomized, double-blind, double-dummy study to evaluate the efficacy, safety, and tolerability of carbavance (meropenem/RPX7009) compared to piperacillin/tazobactam in the treatment of cUTIs, including AP, in adults, vol. NCT02166476. US Department of Health and Human Services, US National Library of Medicine. 2014.
56.
Blizzard TA, Chen H, Kim S, Wu J, Bodner R, Gude C, et al. Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin(R). Bioorg Med Chem Lett. 2014;24:780–5.CrossRefPubMed
57.
Livermore DM, Warner M, Mushtaq S. Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother. 2013;68:2286–90.PubMed
58.
Lucasti C, Vasile L, Sandesc D, Venskutonis D, McLeroth P, Lala M, Rizk ML, Brown ML, Losada MC, Pedley A, Kartsonis NA, Paschke A. Phase 2, Dose-Ranging Study of Relebactam with Imipenem/Cilastatin in Subjects with Complicated Intra-Abdominal Infection. Antimicrob Agents Chemother. 2016.
59.
Merck. Study of the safety, tolerability, and efficacy of MK-7655+imipenem/cilastatin versus imipenem/cilastatin alone for the treatment of complicated urinary tract infection (cUTI) (MK-7655-003). Natiional Library of Medicine. 2012.
Metadaten
Titel
Emerging Issues and Treatment Strategies in Carbapenem-Resistant Enterobacteriaceae (CRE)
verfasst von
Dana R. Bowers
Vanthida Huang
Publikationsdatum
01.12.2016
Verlag
Springer US
Erschienen in
Current Infectious Disease Reports / Ausgabe 12/2016
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-016-0548-3

Weitere Artikel der Ausgabe 12/2016

Current Infectious Disease Reports 12/2016 Zur Ausgabe

Respiratory Infections (F Arnold, Section Editor)

Lung Ultrasound Will Soon Replace Chest Radiography in the Diagnosis of Acute Community-Acquired Pneumonia

Invited Commentary

Thoughts Around the Zika Virus Crisis

Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections

Intra-abdominal Infections, Hepatitis, and Gastroenteritis (T Steiner, Section Editor)

Hepatic and Intra-abdominal Tuberculosis: 2016 Update

Central Nervous System Infections (K Bloch, Section Editor)

Update on the Diagnosis and Management of Neurocysticercosis

Antimicrobial Development and Drug Resistance (A Pakyz, Section Editor)

Antibiotic Resistance in Pediatric Urinary Tract Infections

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Ist Fasten vor Koronarinterventionen wirklich nötig?

04.06.2024 Interventionelle Verfahren in der Kardiologie Nachrichten

Wenn Eingriffe wie eine Koronarangiografie oder eine Koronarangioplastie anstehen, wird häufig empfohlen, in den Stunden zuvor nüchtern zu bleiben. Ein französisches Forscherteam hat diese Maßnahme hinterfragt.

Typ-2-Diabetes: Ernährungsunsicherheit vervierfacht Risiko für schwere Hypoglykämien

04.06.2024 Typ-2-Diabetes Nachrichten

Wenn ältere Menschen mit Typ-2-Diabetes Schwierigkeiten beim Beschaffen und Zubereiten von Mahlzeiten haben, geht dies mit einem deutlich gesteigerten Risiko für schwere Hypoglykämien einher.

Mehr Brustkrebs, aber weniger andere gynäkologische Tumoren mit Levonorgestrel-IUS

04.06.2024 Levonorgestrel Nachrichten

Unter Frauen, die ein Levonorgestrel-freisetzendes intrauterines System (IUS) verwenden, ist die Brustkrebsrate um 13% erhöht. Dafür kommt es deutlich seltener zu Endometrium-, Zervix- und Ovarialkarzinomen.

GLP-1-Agonist Semaglutid wirkt kardio- und nephroprotektiv

03.06.2024 Semaglutid Nachrichten

Der GLP-1-Agonist Semaglutid hat in der FLOW-Studie bewiesen, dass sich damit die Progression chronischer Nierenerkrankungen bei Patienten mit Typ-2-Diabetes bremsen lässt. Auch in kardiovaskulärer Hinsicht war die Therapie erfolgreich.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise